Back to top
more

PetMed Express (PETS)

(Delayed Data from NSDQ)

$3.20 USD

3.20
108,233

-0.04 (-1.23%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $3.18 -0.02 (-0.63%) 7:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 246)

Industry: Internet - Commerce

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AmerisourceBergen to Take Over H. D. Smith for $815 Million

by Zacks Equity Research

AmerisourceBergen (ABC) strives to strengthen core businesses. The H. D. Smith buyout is likely to strengthen the Pharmaceutical Distribution Segment.

    Zacks Equity Research

    DexCom-Lily Partnership to Boost CGM Platform, Customer Base

    by Zacks Equity Research

    DexCom (DXCM) continues to sign deals to boost CGM platform adoption.

      Zacks Equity Research

      Here's Why You Should Offload Fresenius Medical Stock Now

      by Zacks Equity Research

      Fresenius (FMS) grapples with multiple issues. An unfavorable estimate revision trend adds to the woes.

        Zacks Equity Research

        Varian to Open Facility in Brazil, Global Growth in Focus

        by Zacks Equity Research

        Varian's (VAR) strong overseas presence is likely to fortify its foothold in the emerging markets. The recent initiative would boost its presence in Latin America.

          Zacks Equity Research

          Rising Costs Hurt Henry Schein, End-Market Trends a Tailwind

          by Zacks Equity Research

          Higher cost of sales and expenses hurt Henry Schein's (HSIC) gross and operating margin. However, several end market trends like demographics are likely to benefit the company.

            Sweta Killa headshot

            5 Cheap Dividend Growth Stocks for Thanksgiving

            by Sweta Killa

            Stuff dividend stocks with strong growth prospects in your portfolio for market-beating returns this Thanksgiving Day.

              Zacks Equity Research

              Medtronic (MDT) Beats on Q2 Earnings, Reiterates FY18 View

              by Zacks Equity Research

              Medtronic (MDT) rides high on strength in major business segments in Q2.

                Zacks Equity Research

                Patterson Companies (PDCO) Misses on Q2 Earnings, Cuts View

                by Zacks Equity Research

                Patterson Companies (PDCO) missed estimates for both the counts in Q2. A downbeat guidance indicates looming concerns.

                  Zacks Equity Research

                  Medtronic Wins FDA Nod for Azure Pacemakers, Grows in CVG

                  by Zacks Equity Research

                  Medtronic (MDT) strives to improve its Cardiac Rhythm and Heart Failure division.

                    Zacks Equity Research

                    DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay

                    by Zacks Equity Research

                    DENTSPLY SIRONA's (XRAY) renewed distribution deal will help the company gain market traction. However, forex woes remain a concern.

                      Zacks Equity Research

                      McKesson Gains From Distribution Business Amid Pricing Woes

                      by Zacks Equity Research

                      McKesson Corporation's (MCK) Distribution business is driven by market growth and acquisitions. However, pricing remains a concern.

                        Zacks Equity Research

                        Haemonetics (HAE) at 52-Week High: What's Driving the Stock?

                        by Zacks Equity Research

                        Haemonetics (HAE) focuses on development and launch of NexSys PCS plasmapheresis system.

                          Zacks Equity Research

                          Varian's Halcyon Receives Shonin Approval, Grows in Oncology

                          by Zacks Equity Research

                          Varian Medical (VAR) adopts various strategies to boost the Oncology Segment.

                            Zacks Equity Research

                            AmerisourceBergen's PharMEDium Slows Down, Competition Rife

                            by Zacks Equity Research

                            AmerisourceBergen's (ABC) prospects hurt by tepid performance at PharMEDium. Also, steep competition is a cause for concern.

                              Zacks Equity Research

                              Align Technology-Glidewell Dental Deal to Boost iTero Uptake

                              by Zacks Equity Research

                              Align Technology (ALGN) progresses with deals to boost the Scanners and Services segment.

                                Zacks Equity Research

                                Intuitive Surgical Hits a 52-Week High on Solid Prospects

                                by Zacks Equity Research

                                The market is upbeat about Intuitive Surgical's (ISRG) solid procedure performance in Asia, with growth in China, Japan and Korea.

                                  Zacks Equity Research

                                  Wright Medical (WMGI) Rides on Strong Portfolio & Innovation

                                  by Zacks Equity Research

                                  Wright Medical (WMGI) is focused on product innovation through research and development. However, lackluster international performance of the lower extremities segment is a matter of concern.

                                    Zacks Equity Research

                                    Genomic Health Cancer Diagnostic Tests Grow Amid Cost Woes

                                    by Zacks Equity Research

                                    Revenues at Genomic Health (GHDX) improve year over year in Q3, driven by solid performances in the United States and internationally. However, rising operating losses continue to be a spoiler.

                                      Zacks Equity Research

                                      Medtronic Stock Dips on Preliminary Sales Drag, CRHF to Grow

                                      by Zacks Equity Research

                                      Medtronic's (MDT) latest preliminary sales update for the second quarter of fiscal 2018 holds the market in a bleak light.

                                        Zacks Equity Research

                                        Ecolab (ECL) to Refinance $375M Worth of Notes, Reduce Debt

                                        by Zacks Equity Research

                                        Ecolab (ECL) plans to reduce debt by refinancing notes with a lower coupon rate.

                                          Zacks Equity Research

                                          Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength

                                          by Zacks Equity Research

                                          Luminex's (LMNX) collaborative agreements with several companies should help expand the adoption of its products.

                                            Zacks Equity Research

                                            Intuitive Surgical (ISRG) to Gain From Procedural Business

                                            by Zacks Equity Research

                                            Intuitive Surgical's (ISRG) sales to gain from on da Vinci system and procedural growth in general surgery, oncology, urology and gynecology.

                                              Zacks Equity Research

                                              LabCorp Reports New Use of Agilent's Cancer Diagnostic Test

                                              by Zacks Equity Research

                                              The testing of the clinical studies needed to approve PD-L1 IHC 28-8 pharmDx assay's new indications were performed at LabCorp's (LH) Center for Molecular Biology and Pathology laboratory.

                                                Zacks Equity Research

                                                Here's Why Investors Should Buy Myriad Genetics Right Now

                                                by Zacks Equity Research

                                                Myriad Genetics' (MYGN) recent collaborations are encouraging. Also, the company banks on the GeneSight and EndoPredict portfolios.

                                                  Zacks Equity Research

                                                  Illumina Introduces NextSeq 550Dx, Updates Use of MiSeqDx

                                                  by Zacks Equity Research

                                                  Illumina (ILMN) expands NGS platform. The company has a solid diagnostic NGS portfolio, which includes NextSeq 550Dx and MiSeqDx.